Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

NYT Best Seller Dr. Kate Clifford Larson on Fannie Lou Hamer & the Mississippi Civil Rights Movement

This week on “The Learning Curve," co-hosts Cara Candal and Gerard Robinson talk with Dr. Kate Clifford Larson, a New York Times best-selling biographer of Harriet Tubman and Fannie Lou Hamer. Kate shares why she has written about these historical African-American figures, and how she thinks parents, teachers, and schools can draw on their lives to talk about race.

Valhalla Foundation’s Nancy Poon Lue on STEM Access & Equity

This week on “The Learning Curve," host Gerard Robinson talks with Nancy Poon Lue, incoming Senior Director at the Valhalla Foundation, where she will be leading their K-12 math funding initiatives. Nancy shares her recent work with the EF+Math Program, some of the challenges America has faced in ensuring students have a strong grounding in math and science, and the kinds of results she aims to achieve for kids in all ZIP codes. 

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Trevor Mattos Shows How Massachusetts Runs on Immigrants

This week on JobMakers, Host Denzil Mohammed talks with Trevor Mattos, research manager at Boston Indicators, the research center at The Boston Foundation, which educates state and local leaders on the important contributions immigrants are making. They discuss the urgency of this work, particularly in a time of divisive disinformation about immigrants and the uncertainty of the pandemic, and some of the surprising findings on the disproportionately large impact immigrant workers, entrepreneurs and innovators are having on the local economy

Yale’s Pulitzer-Winning Prof. David Blight on Frederick Douglass, Slavery, & Emancipation

This week on “The Learning Curve," Cara Candal and guest co-host Derrell Bradford talk with David Blight, Sterling Professor of American History and director of the Gilder Lehrman Center for the Study of Slavery, Resistance, and Abolition at Yale University. He is the author of the Pulitzer Prize-winning biography, Frederick Douglass: Prophet of Freedom.

UVA Prof. E.D. Hirsch, Jr. on Core Knowledge, Equity, & Educating Citizens

This week on “The Learning Curve," co-hosts Cara Candal and Gerard Robinson talk with Professor E.D. Hirsch, Jr., founder and chairman of the Core Knowledge Foundation, professor emeritus at the University of Virginia, and acclaimed author of the books, Cultural Literacy: What Every American Needs to Know and How to Educate a Citizen: The Power of Shared Knowledge to Unify a Nation.

“Key of the Gulf” – Exploring Cuba – 35 Resources for Parents & Students

Castro’s despotism, the Cold War, the Cuban Missile Crisis, and the Embargo, remains the Cuban people – vibrant, creative, pious, and poor, who have continued to inspire and awe with their smiles, culture, music, dance, food, tobacco, resilience, and hopes. With the desire of passing along some of this magic to American families, students, teachers, and schools, we’re providing a variety of resources to educate our people about their neighbors, who live a mere 100 miles from our shores, in Cuba.

Human Rights Advocate Kristina Arriaga on Cuba, Religious Liberty, & Cancel Culture

This week on “The Learning Curve," co-hosts Cara Candal and Gerard Robinson talk with Kristina Arriaga, president of Intrinsic, a strategic communications firm, and former vice chair of the U.S. Commission on International Religious Freedom. Kristina shares her family’s experiences fleeing Castro’s communist regime in Cuba and other hardships, and how her background has shaped her commitment to religious liberty.

Pandemic Pension Payout: Essential COVID-19 Public Workers Rewarded Whether Essential or Working

Hubwonk host Joe Selvaggi talks with Pioneer Institute’s Director of Research and former Massachusetts Inspector General and State Representative Greg Sullivan about HB 2808, COVID-19 Essential Employee Retirement Credit Bonus, discussing the merits of the recently proposed joint bill, its cost, and our current public debt burden in the Commonwealth.

MBTA Ridership Trends Compared to Public Transportation Agencies Nationwide

0 Comments
/
The COVID-19 pandemic had a devastating effect on our economy,…

Public Statement on Implementation of the Charitable Giving Deduction

Despite being awash in cash, the state Legislature just overrode Gov. Charlie Baker’s veto of a provision to delay by yet another year a tax deduction for charitable donations. Rep. Mark Cusack, House chair of the Joint Committee on Revenue, said “it doesn’t mean no, just not now.” If not now, when?

The Globe’s Ornaments – Celebrating the Great Cities of the Ages – 35 Resources for Parents & Students

Celebrating the Great Cities of the Ages - This is part of Pioneer’s ongoing series of blogs on curricular resources for parents, teachers, and students during COVID-19.